New Specialist Investors

RNS Number:3800O
Cytomyx Holdings PLC
04 July 2005


For immediate release                                              4th July 2005

                              CYTOMYX HOLDINGS PLC
                          ("Cytomyx" or "the Company")

            Notification of New and Specialist Healthcare Investors

Cytomyx Holdings PLC (AIM: CYX) is pleased to announce that, following the
recent acquisition of Aptus Pharmaceuticals Inc ("Aptus"), three significant
investors have notified the Directors of Cytomyx that they have an interest in
the Company.

Emerging Technology Partners, LLC ("ETP"), a specialist life science venture
fund based in Maryland, USA, that provides capital and supports management in
life science companies, now owns a 15.9 per cent of the enlarged share capital
of Cytomyx.  Assuming the second tranche of consideration shares are allotted in
full, ETP will own a maximum of 17.2 per cent of the share capital of Cytomyx.

Maryland Department of Business and Economic Development and Fujisawa
Investments are both former investors in Aptus and now have a respective 3.96
per cent and 3.71 per cent stake in Cytomyx.

Notified new interest in Cytomyx:

Shareholder                           Number of ordinary  Percentage of issued
                                         shares held         ordinary share
                                                                 capital
ETP/FBR Venture Capital LLC               9,547,740               15.9%
Maryland Department of Business and 
Economic Development                      2,375,763               3.96%
Fujisawa Investments                      2,229,084               3.71%

Wei-Wu He Ph.D., General Partner at ETP, commented: "We are very pleased to have
become a major investor in Cytomyx through their recent acquisition of Aptus
Pharmaceuticals. We believe that the key factor enabling success in the
biotechnology industry is the partnership of experienced management, world-class
science and visionary financing. At ETP we use our extensive network to bring
these critical pieces together, providing a solid foundation for the growth of a
company. We believe that Cytomyx can build upon its current world-class
technology base and become an important industry participant as it continues to
develop new technologies that enhance the productivity of drug discovery
research."

Mike Kerins, Cytomyx' Chief Executive, said: "I am very pleased to welcome these
new shareholders to Cytomyx.  Emerging Technology Partners, is a major new
shareholder in the Company. ETP is a sophisticated specialist investor in our
field and I am very glad that they have recognized the value of our technology
and the strength of our team. The proprietary screening technology that we
acquired with Aptus Pharmaceuticals will make a significant contribution to our
future revenues and is an excellent fit with our current technologies which aim
to make drug discovery research more productive."

For further information, please contact:

Cytomyx Holdings plc                                     [phone]
Mike Kerins, Chief Executive

Buchanan Communications                                  [phone]
Mark Court/Mary-Jane Johnson

About Cytomyx Holdings plc

Cytomyx Holdings plc is a rapidly growing life science company based in
Cambridge, UK. The Company's primary focus is on developing novel technologies
that assist pharmaceutical and biotechnology companies in their efforts to
develop new treatments more effectively. This it does by providing solutions
that provide early insights into the likely efficacy and safety profile of new
drugs in development. The Company has two main areas of expertise: the use of
human clinical samples in understanding the linkage between gene expression and
disease and the development of cell-based assays that are used to predict
efficacy and potential toxicity in new drugs.  Cytomyx is listed on the AIM
market of the London Stock Exchange (CYX.L). For more information visit
www.cytomyx-holdings.com

                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
MSCUASVRVRRBRAR